An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
- PMID: 25657821
- PMCID: PMC4318134
- DOI: 10.1186/1866-1955-6-46
An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
Abstract
Background: Mucopolysaccharidosis type-III (MPS III) is an autosomal recessive lysosomal storage disorder. It causes progressive physical and cognitive decline and has been linked to increased incidences of behavioural problems.
Methods: Data on the behaviour and adaptive skills of 20 children with MPS III and 25 children with intellectual disability (ID) (17 included in analysis) were gathered via parental report questionnaire. The frequencies of different types of behaviour displayed by children with MPS III and children with ID were compared across two age categories.
Results: The total frequency of challenging behaviours displayed by children aged 2-9 years with MPS III and ID was not significantly different. Behaviours associated with hyperactivity, orality, unusual body movements and inattention were seen significantly more frequently in 2-9 year olds with MPS III than in those with ID. Children aged 10-15 years with MPS III showed significantly fewer problem behaviours than a contrasting group with ID. The frequency of challenging behaviours displayed by children with MPS III and their adaptive skills was found to decrease with age.
Conclusions: Behaviours relating to hyperactivity, orality, unusual body movements and inattention are part of the behavioural phenotype of the middle phase of MPS III. The late phase of MPS III is associated with low rates of problem behaviour and loss of adaptive skills. Therefore, families with a child with MPS III may benefit from a different type of clinical service when the child is aged 2-9 years, than when aged 10-15 years.
Keywords: Behavioural phenotype; MPS III; Mucopolysaccharidosis; Sanfilippo syndrome.
Figures
Similar articles
-
Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).J Inherit Metab Dis. 2013 Mar;36(2):281-91. doi: 10.1007/s10545-012-9558-y. Epub 2012 Nov 15. J Inherit Metab Dis. 2013. PMID: 23151683
-
What Can We Learn from the Parents of Children Affected with Mucopolysaccharidosis Type III-A in Israel?Mol Syndromol. 2022 Feb;13(1):45-49. doi: 10.1159/000519099. Epub 2021 Dec 15. Mol Syndromol. 2022. PMID: 35221874 Free PMC article.
-
Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families.Acta Paediatr. 2012 Sep;101(9):985-92. doi: 10.1111/j.1651-2227.2012.02680.x. Epub 2012 May 24. Acta Paediatr. 2012. PMID: 22452449
-
Challenging behavior in mucopolysaccharidoses types I-III and day-to-day coping strategies: a cross sectional explorative study.Orphanet J Rare Dis. 2020 Oct 2;15(1):275. doi: 10.1186/s13023-020-01548-9. Orphanet J Rare Dis. 2020. PMID: 33008435 Free PMC article. Review.
-
Musculoskeletal manifestations of Sanfilippo Syndrome (mucopolysaccharidosis type III).J Pediatr Orthop. 2011 Jul-Aug;31(5):594-8. doi: 10.1097/BPO.0b013e31821f5ee9. J Pediatr Orthop. 2011. PMID: 21654471 Review.
Cited by
-
Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses.Ital J Pediatr. 2018 Nov 16;44(Suppl 2):121. doi: 10.1186/s13052-018-0561-2. Ital J Pediatr. 2018. PMID: 30442188 Free PMC article. Review.
-
Psychobehavioral factors and family functioning in mucopolysaccharidosis: preliminary studies.Front Public Health. 2024 Jan 24;12:1305878. doi: 10.3389/fpubh.2024.1305878. eCollection 2024. Front Public Health. 2024. PMID: 38327584 Free PMC article.
-
Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome.J Patient Rep Outcomes. 2022 Apr 25;6(1):40. doi: 10.1186/s41687-022-00447-w. J Patient Rep Outcomes. 2022. PMID: 35467223 Free PMC article.
-
Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment.Neurol Ther. 2021 Jun;10(1):197-212. doi: 10.1007/s40120-020-00226-z. Epub 2020 Dec 2. Neurol Ther. 2021. PMID: 33263924 Free PMC article.
-
Increasing precision in the measurement of change in pediatric neurodegenerative disease.Mol Genet Metab. 2022 Sep-Oct;137(1-2):201-209. doi: 10.1016/j.ymgme.2022.09.001. Epub 2022 Sep 8. Mol Genet Metab. 2022. PMID: 36115283 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources